Full Press Release Details
Viking Therapeutics and Kennedy Krieger Institute Sign Collaboration Agreement to Evaluate Novel Thyroid Beta Agonists for X-Linked Adrenoleukodystrophy (X-ALD).
VKTX
Viking Therapeutics and Kennedy Krieger Institute Sign Collaboration Agreement to Evaluate Novel Thyroid Beta Agonists for X-Linked Adrenoleukodystrophy (X-ALD)
Key Takeaway: Viking Therapeutics and Kennedy Krieger Institute Sign Collaboration Agreement to Evaluate Novel Thyroid Beta Agonists for X-Linked Adrenoleukodystrophy (X-ALD)